Evoke Wealth, LLC Vertex Pharmaceuticals Inc Transaction History

Evoke Wealth, LLC

$3.59 Trillion
Q4 2024

A detailed history of Evoke Wealth, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Evoke Wealth, LLC holds 1,071 shares of VRTX stock, worth $491,589. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,071

Previous 988 8.4%

Holding current value

$491,589

Previous $459 Million 6.14%

% of portfolio

0.01%

Previous 0.01%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 10, 2025	BUY	$396.64 - $516.74 $32,921 - $42,889	83 Added 8.4%	1,071 $431 Million
Q3 2024 Nov 13, 2024	BUY	$460.0 - $505.78 $454,480 - $499,710	988 New	988 $459 Million
Q1 2024 May 15, 2024	BUY	$407.69 - $446.08 $384,451 - $420,653	943 New	943 $394,000
Q2 2022 Aug 04, 2022	SELL	$234.96 - $292.55 $1,879 - $2,340	-8 Reduced 4.6%	166 $47,000
Q1 2022 May 10, 2022	BUY	$221.42 - $260.97 $9,521 - $11,221	43 Added 32.82%	174 $45,000
Q3 2021 Nov 12, 2021	SELL	$181.39 - $202.99 $1,088 - $1,217	-6 Reduced 4.38%	131 $23,000
Q2 2021 Aug 05, 2021	SELL	$187.49 - $221.1 $7,874 - $9,286	-42 Reduced 23.46%	137 $28,000
Q1 2021 May 13, 2021	BUY	$207.02 - $241.31 $7,452 - $8,687	36 Added 25.17%	179 $38,000
Q4 2020 Feb 12, 2021	BUY	$207.01 - $276.09 $1,656 - $2,208	8 Added 5.93%	143 $34,000
Q2 2020 Aug 10, 2020	SELL	$225.48 - $295.8 $676 - $887	-3 Reduced 2.17%	135 $39,000
Q1 2020 May 07, 2020	SELL	$199.77 - $247.81 $62,528 - $77,564	-313 Reduced 69.4%	138 $32.8 Million
Q4 2019 Feb 07, 2020	SELL	$166.71 - $223.91 $7,668 - $10,299	-46 Reduced 9.26%	451 $98.7 Million
Q3 2019 Nov 12, 2019	BUY	$166.23 - $187.09 $82,616 - $92,983	497 New	497 $84.2 Million

Others Institutions Holding VRTX

# of Institutions

1,745

Shares Held

227M

Call Options Held

1.53M

Put Options Held

1.4M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $118B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Evoke Wealth, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Evoke Wealth, LLC with notifications on news.

Account